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Highlights
 Established blood tests can be used in primary care to
stratify patients with fatty liver disease.
 A 2-step pathway (FIB-4 followed by ELFTM if required)
reduced unnecessary referrals by 80%.
 This pathway also improved the detection of cases of
advanced fibrosis 5-fold and cirrhosis 3-fold.
 This pathway can be used in primary care to identify patients
who might benefit from referral to liver specialists.
 This should reduce unnecessary referrals while at the same
time improving the detection of cirrhosis.Ankur Srivastava, Ruth Gailer, Sudeep
Tanwar, ..., Sarah Morgan, Emmanuel A.
Tsochatzis, William Rosenberg
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Lay summary
Non-alcoholic fatty liver disease effects
up to 30% of the population but only a
minority of cases develop liver disease.
Our study has shown that established
blood tests can be used in primary care to
stratify patients with fatty liver disease,
leading to a reduction in unnecessary
referrals by 80% and greatly improving
the detection of cases of advanced fibrosis
and cirrhosis.Genetic and Metabolic Diseases. This is an open access article under the CC BY-NC-ND
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Background & Aims: The development of non-invasive liver
ﬁbrosis tests may enable earlier identiﬁcation of patients with
non-alcoholic fatty liver disease (NAFLD) requiring referral to
secondary care. We developed and evaluated a pathway for
the management of patients with NAFLD, aimed at improving
the detection of cases of advanced ﬁbrosis and cirrhosis, and
avoiding unnecessary referrals.
Methods: This was a prospective longitudinal cohort study,
with analyses performed before and after introduction of the
pathway, and comparisons made to unexposed controls. We
Introduction
Non-alcoholic fatty liver disease (NAFLD) is the commonest
cause of deranged liver blood tests (LFTs) in primary care in Eur-
ope and North America,1 with an estimated prevalence of 25–
30% in the adult population.2 Only a minority of people with
NAFLD (5%) develop clinically signiﬁcant liver disease,2 but
the burden is such that NAFLD is predicted to be the leading
indication for liver transplantation within a decade.3
The majority of patients with NAFLD are followed up in the
community by general practitioners (GPs). Liver ﬁbrosis severity
is the key determinant of liver-related outcomes in NAFLD.4–6
However, identifying patients with signiﬁcant ﬁbrosis who
might beneﬁt from early specialist intervention is challenging.
As clinical assessment is a poor discriminator of ﬁbrosis, such
patients progress silently until cirrhosis leads to complications.
Accurate ﬁbrosis assessment in primary care is limited by a reli-
ance on LFTs, which correlate poorly with ﬁbrosis7,8 and limited
access to discriminatory ﬁbrosis tests. Thus, current manage-
ment strategies are inefﬁcient in identifying patients for special-
ist referral. Patients with mild disease are often referred for
specialist review when the appropriate preventative interven-used a 2-step algorithm combining the use of Fibrosis-4 score
followed by the ELFTM test if required.
Results: In total, 3,012 patients were analysed. Use of the path-
way detected 5 times more cases of advanced ﬁbrosis (Kleiner
F3) and cirrhosis (odds ratio [OR] 5.18; 95% CI 2.97–9.04;
p <0.0001), while reducing unnecessary referrals from primary
care to secondary care by 81% (OR 0.193; 95% CI 0.111–0.337;
p <0.0001). Although it was used for only 48% of referrals, signif-
icant beneﬁts were observed in practices exposed to the path-
way compared to those which were not, with unnecessary
referrals falling by 77% (OR 0.23; 95% CI 0.658–0.082;
p = 0.006) and a 4-fold improvement in detection of cases of
advanced ﬁbrosis and cirrhosis (OR 4.32; 95% CI 1.52–12.25;
p = 0.006). Compared to referrals made before the introduction
of the pathway, unnecessary referrals fell from 79/83 referrals
(95.2%) to 107/152 (70.4%), representing an 88% reduction in
unnecessary referrals when the pathway was followed
(OR 0.12; 95% CI 0.042–0.349; p <0.0001).
Keywords: FIB-4; ELF; Steatohepatitis; Non-invasive ﬁbrosis test; Cirrhosis; Cost
effectiveness; Clinical management; NAFLD.
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Conclusions: The use of non-invasive blood tests for liver ﬁbro-
sis improves the detection of advanced ﬁbrosis and cirrhosis,
while reducing unnecessary referrals in patients with NAFLD.
This strategy improves resource use and beneﬁts patients.
Lay summary: Non-alcoholic fatty liver disease effects up to
30% of the population but only a minority of cases develop liver
disease. Our study has shown that established blood tests can be
used in primary care to stratify patients with fatty liver disease,
leading to a reduction in unnecessary referrals by 80% and
greatly improving the detection of cases of advanced ﬁbrosis
and cirrhosis.
 2019 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).019 vol. 71 j 371–378
care while those with an ELF score ≥9.5 were recommended
for referral to secondary care.16,17
Research Article Genetic and Metabolic Diseasestions of lifestyle changes can be delivered effectively in primary
care.9,10 Conversely, patients with advanced ﬁbrosis or cirrhosis
who will beneﬁt from specialist interventions including clinical
trials and cirrhosis surveillance often remain undetected until
they present with complications of cirrhosis, including hepato-
cellular carcinoma. This ineffective management contributes
to the poor outcomes associated with liver disease and the
increasing trends in NAFLD-related morbidity and mortality.
The evolution of non-invasive liver ﬁbrosis tests has created
the opportunity for GPs to use these tests in innovative path-
ways that permit earlier identiﬁcation of patients with chronic
liver disease and subsequent access to specialist care.11 An
example of this approach is outlined in the recent British Soci-
ety for Gastroenterology guidance on the management of
abnormal LFTs that recommends the use of non-invasive tests
to stratify patients at risk of chronic liver disease.12
Whilst there is little evidence supporting the application of
non-invasive tests in community settings, with only 1 study
focusing on patients with NAFLD,13 guidelines recommend a
2-tier approach to detect the presence of advanced ﬁbrosis in
NAFLD using either Fibrosis-4 (FIB-4) or NAFLD Fibrosis score,
as an inexpensive ﬁrst screen, in a combined cut-off approach
with indeterminate scores retested using more sensitive and
speciﬁc tests, enhanced liver ﬁbrosis (ELFTM) or FibroScan, that
are more costly.14
Through broad consultation, a care pathway for patients
identiﬁed with NAFLD in primary care was developed using
non-invasive ﬁbrosis assessment (FIB-4 followed by ELF) to
stratify patients to either remain in primary care or to be
referred to secondary care. We present a prospective evaluation
of the performance of the pathway 2 years after its introduction.
Materials and methods
Study setting and design
The Camden and Islington NAFLD Pathway (hereafter the
‘‘NAFLD pathway”) was developed as a service innovation in
conjunction with the primary care clinical commissioning
groups (CCGs) of the London boroughs of Camden and Islington
(C&I), between April 2013 and March 2014, before being intro-
duced into practice. The NAFLD pathway working group met
regularly to develop a pathway for the management of patients
with NAFLD aiming to identify patients with advanced liver
ﬁbrosis (≥Kleiner F3), who might beneﬁt from referral to sec-
ondary care for specialist hepatology review while identifying
and managing patients with lesser degrees of ﬁbrosis in primary
care. The composition and aims of the working group including
patient and public involvement are described in the supplemen-
tary information. The pathway evaluation was conducted
between March 2014 and May 2016 with the aim of determin-
ing the impact of the pathway in reducing unnecessary referrals
and increasing the detection and referral of patients with
advanced ﬁbrosis. The pathway was introduced into C&I CCGs
representing 2 of the 25 CCGs making referrals to the liver spe-
cialist services at The Royal Free London NHS Foundation Trust,
The Whittington Hospital NHS Trust and University College Lon-
don Hospitals NHS Foundation Trust, accounting for 43% of the
referrals in 2012–13. All practices within the 2 CCGs adopted
the pathway, but individual GPs within C&I were at liberty to
follow it or to use standard care for each referral. The evaluation
was conducted as a longitudinal study in which C&I represented
the CCGs exposed to the pathway and the remaining 23 CCGs
represented the control CCGs.
372 Journal of Hepatology 2The Camden and Islington NAFLD pathway
All individuals aged 18 and over attending their GP with a new
or established diagnosis of NAFLD were eligible for entry. For
purposes of the pathway, NAFLD was diagnosed in patients with
steatosis on ultrasound, negative screens for other causes of
liver disease and no alcohol excess (deﬁned as >21 units of alco-
hol/week in males, >14 units/week in females).
The pathway consisted of a 2-step non-invasive test assess-
ment, starting with the calculation of the FIB-4 score (Fig. 1).
Patients with FIB-4 <1.30 were deemed to be at low risk of
advanced ﬁbrosis (<F3) and remained in primary care.15 Primary
care management consisted of treatment of cardiovascular risks
and diabetes, annual LFTs, and re-assessment of the risk of
advanced ﬁbrosis after 3–5 years. Patients with FIB-4 >3.25
were deemed to be at high risk of advanced ﬁbrosis and were
recommended for referral to secondary care for specialist
assessment. Patients with indeterminate FIB-4 values (≥1.30
and <3.25) had second tier testing with an ELF test. Patients
with ELF scores <9.5 were recommended to remain in primaryEvaluation of standard care 2012–2013 prior to pathway
introduction
A retrospective audit of referrals to secondary care by GPs was
undertaken between 01/03/2012 and 28//02/2013 to determine
the referrers’ ability to identify patients with advanced ﬁbrosis
using standard care. The case records of all patients assigned a
Read code and referred with a diagnosis of NAFLD were
reviewed by hepatologists in the receiving hospital and evalu-
ated for evidence of advanced ﬁbrosis/cirrhosis (≥F3) based on
a composite of history, physical examination, blood tests, imag-
ing, FibroScan, and liver histology when available. FIB-4 scores
were calculated and patients with FIB-4 <1.30 were deemed
to have no evidence of liver ﬁbrosis and thus referred inappro-
priately. Referrals originating from primary care practices
within the C&I CCGs were analysed separately from those
referred from other CCGs.
<1.30
Raised ALT with no excess EtOH,
negative CLD screen ± fatty liver on
ultrasound
FIB-4
1.30-3.25
>3.25
ELF<9.5 >9.5
HIGH risk of
≥F3 fibrosis
LOW risk of
≥F3 fibrosis
Manage fatty liver in primary care
- Treat metabolic syndrome
- Weight loss
- Annual LFTs
- Re-assess fibrosis in 3-5 years
  using pathway
Refer to Hepatologist
- For assessment of CLD
- Consideration of clinical trials
- Consideration of HCC/ variceal
  surveillance
Fig. 1. The Camden and Islington NAFLD pathway. CLD, chronic liver
disease; ELF, enhanced liver ﬁbrosis; EtOH, ethanol; FIB-4, Fibrosis-4; HCC,
hepatocellular carcinoma; LFTs, liver function tests; NAFLD, non-alcoholic
fatty liver disease. (This ﬁgure appears in colour on the web.)019 vol. 71 j 371–378
Pathway evaluation
Following introduction of the NAFLD pathway, data were col-
lected on the outcomes of NAFLD referrals for patients seen at
the secondary care sites. The CCG of the referral origin and
use of the NAFLD pathway or standard care were recorded.
The primary care electronic patient record systems (EMISWeb,
Egton Medical Information Systems) were interrogated cen-
trally to obtain data on NAFLD diagnosis and use of the pathway
to stratify patients for referral using Read codes in primary care.
Secondary care electronic medical records were interrogated to
extract data related to patient demographics, secondary care
management, ﬁbrosis staging and clinical events.
The diagnostic performance of the NAFLD pathway in detect-
ing cases of advanced ﬁbrosis was assessed against a reference
standard composite clinical evaluation performed by expert
hepatologists blinded to the use of the NAFLD pathway, as
described above. All decisions were reviewed by the study team
(AS and WMR) and any differences of opinion between the
experts and the study team (<10% of cases) were resolved
through discussion.
Secondary care evaluation of the patients consisted of more
analyses and in most cases a FibroScan, performed indepen-
dently of the use of the pathway. A subset of 35/152 patients,
referred from C&I and deemed to have advanced ﬁbrosis, under-
went liver biopsy following clinical assessment. Biopsies were
staged for ﬁbrosis by a single histopathologist who was blinded
to use of the pathway (Table S1).
The distribution of FIB-4 scores in patients assessed by C&I
GPs before and after introduction of the pathway was compared
to look for evidence of bias in patient selection.
Outcomes
The primary outcome was the reduction in the proportion of
patients with NAFLD referred to secondary care who did not
have evidence of advanced ﬁbrosis based on clinical evaluation
and were thus deemed to have been referred unnecessarily.
Secondary outcomes included:
 The number of cases and proportion of those referred
who were deemed to have advanced ﬁbrosis or cirrhosis
after assessment by a liver specialist (true positive rate).
 Proportion of patients diagnosed with NAFLD avoiding
referral after primary care stratiﬁcation.
 Number of patients coded for NAFLD by GP before and
after introduction of the pathway.
Sensitivity analyses were conducted to determine the impact
of using age-speciﬁc cut-offs for FIB-4 to triage patients.18 The
impact of using alternative ELF cut-offs for detection of
advanced ﬁbrosis was investigated including the manufacturer’s
recommendation (ELF = 9.8) and the threshold recommended in
recent NICE guidance on NAFLD (ELF = 10.51).19
In order to determine the effectiveness of the pathway com-
pared to standard care, the outcomes of patients referred using
the NAFLD pathway were compared to those of patients referred
from C&I prior to introduction of the pathway; and to those of
patients referred using standard care from C&I and from other
CCGs during the evaluation period following introduction of
the pathway.
In order to determine the effectiveness of the introduction of
the pathway to all general practices across the 2 CCGs of C&I,
outcomes for all patients referred from C&I, irrespective of the
use of the NAFLD pathway, were compared to those of patients
r
d
S
S
I
o
a
w
u
E
T
D
o
r
b
c
d
R
P
B
p
t
d
(
p
(
t
(
1
w
m
l
c
t
a
1
S
t
B
a
b
i
f
2
i
o
(
r
o
s
e
w
(
t
O
JOURNAL 
OF HEPATOLOGY
Journal of Hepatology 20eferred from all other CCGs where the pathway was not intro-
uced during the evaluation period.
tatistical analyses
tatistical analyses were performed using SPSS (version 22, SPSS
nc., Chicago, IL, USA). The odds ratios (ORs) for differences in
utcomes for patients managed in accordance with the pathway
nd those managed using standard care were calculated, along
ith 95% CIs and chi-square tests for statistical signiﬁcance
sing Medcalc statistical software (MedCalc Software 2018).
thical approval
he Royal Free London NHS Foundation Trust Research and
evelopment Department judged this study to be an evaluation
f a service improvement innovation. Therefore, this study was
egistered for audit (EDGE ID:122031) but not subject to review
y an independent ethics committee, and individual patient
onsent was not sought. All activities were performed in accor-
ance with the guidelines of the Helsinki Declaration.
esults
articipants
etween 01/03/2014 and 31/05/2016 in C&I CCGs, 3,012
atients were coded as having NAFLD, with an equal distribu-
ion in the numbers entered into the NAFLD pathway and stan-
ard care (Table 1). Seventy-two per cent of eligible practices
52/72) used the NAFLD pathway to stratify a proportion of their
atients. Patients entered into the NAFLD pathway were older
54.4 years vs. 51.5, p <0.001), had a higher prevalence of trea-
ed type 2 diabetes (27.6% vs. 21.0%, p <0.001) and hypertension
41.7% vs. 33.0%, p <0.001), and less dyslipidaemia (13.5% vs.
4.6%, p <0.001) than patients managed by standard care. There
ere no signiﬁcant differences in Q-Risk2 score, glycated hae-
oglobin, aminotransferases, platelet counts or high-density
ipoprotein. The distribution of calculated FIB-4 scores in 695
ases for which the data were available was identical between
he patients managed using the NAFLD pathway and those man-
ged using standard care <1.30: 513/695 (73.8%); 1.30–3.25:
62/695 (23.3%); >3.25: 20/695 (2.9%).
tratification of patients with NAFLD in primary care using
he NAFLD pathway
etween 2012–13 and 2014–16 the number of patients
ssigned Read codes in the electronic patient records per annum
y GPs in C&I increased from 601/year to 1,506/year, represent-
ng a 2.5-fold increase. The number of cases of NAFLD referred
rom C&I GPs nearly doubled from 83 in 2012–13 to 329 in
014–16 (164.5/year). However, considering the increased cod-
ng, the proportion of NAFLD coded patients referred to sec-
ndary care from all C&I GPs fell from 13.8% (83/601) to 10.9%
165/1,506).
Comparison of the distribution of FIB-4 scores of patients
eferred for NAFLD by C&I GPs before and after the introduction
f the NAFLD pathway revealed no evidence of bias in patient
election (Table S2).
Over 2 years, 1,452 patients were risk-stratiﬁed for the pres-
nce of advanced ﬁbrosis using FIB-4 (Fig. 2). FIB-4 score <1.30
as calculated in 1,022 patients (71.3%), whilst 43 patients
3.0%) had FIB-4 >3.25. The remaining 387 patients had an inde-
erminate FIB-4 score (1.30–3.25) and proceeded to an ELF test.
f these, 155 (40.0%) had ELF <9.5, and 232 (60.0%) had ELF >9.5.19 vol. 71 j 371–378 373
ﬁed by liver biopsy (n = 14, 31.1%), FibroScan (n = 25, 55.6%) or
radiological features of cirrhosis (n = 6, 13.3%). Of the 45
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374 Journal of Hepatology 2In total, 1,177 patients were stratiﬁed as being at low risk of
advanced ﬁbrosis (81.1%) and remained in the primary care
setting. The remaining 275 patients (18.9%) were recom-
mended for referral to a specialist for further investigation.
The GPs referred 152 of these 275 patients (55.3%) for specialist
investigation within the follow-up period (Fig. 3). To interro-
gate the reasons for non-referral, 3 surgeries were audited
including 32 of the non-referrals. In this sub-group, reasons
for non-referral included: patient already under the care of a
hepatologist (n = 4), inappropriate for pathway due to alcohol
excess (n = 2), comorbidity precluding need for specialist
review (n = 1), continued monitoring in primary care (n = 3)
awaiting outpatient appointment at time of evaluation
(n = 2), and lost to follow-up (n = 2). Reasons were not
recorded for 18 patients. Process evaluation revealed that
37/152 (24.3%) referrals had normal LFTs, and therefore should
not have been on the pathway. Of the patients referred to sec-
ondary care using the NAFLD pathway, hepatologists judged
that 29.6% had advanced ﬁbrosis and 14.5% had cirrhosis com-
pared to 4.8% and 3.6%, respectively, prior to introduction of
the NAFLD pathway. Advanced ﬁbrosis or cirrhosis was identi-patients with advanced ﬁbrosis or cirrhosis, 7 patients were
referred due to FIB-4 alone (of whom 6 were cirrhotic) and
38 due to the combination of FIB-4 and ELF (Fig. 4).
Referrals made using the NAFLD pathway compared to
standard care during the evaluation period
Comparisons were made between referrals from C&I GPs using
the pathway to GPs in C&I using standard care; and to GPs
using standard care in other CCGs where the pathway had
not been discussed or introduced (Tables 2 and 3). The NAFLD
pathway was 5 times better at selecting cases of advanced
ﬁbrosis and cirrhosis than standard care. When compared to
standard care referrals from C&I, use of the pathway improved
detection of advanced ﬁbrosis and cirrhosis 4.9-fold (OR 4.90;
95% CI 2.56–9.36; p <0.0001) and when compared to referrals
made by GPs outside C&I using standard care the pathway
improved detection 5.2-fold (OR 5.18; 95% CI 2.97–9.04;
p <0.0001). This equates to an 81% reduction in unnecessary
referrals from primary care (OR 0.193; 95% CI 0.111–0.337;
p <0.0001) when the pathway was used.
Hepatologists diagnosed more cases of cirrhosis amongst
patients referred using the NAFLD pathway compared to those
referred by C&I GPs using standard care (22/152 [14.5%] com-
pared to 10/177 [5.6%]). This equates to nearly a 3-fold
improvement in the detection of cases of cirrhosis (OR 2.83;
95% CI 1.29–6.18; p = 0.009). The number of referrals required
to detect 1 case of advanced ﬁbrosis was 3.4 using the pathway
compared to 12.6 using standard care.
Comparison of the NAFLD pathway with standard care pro-
vided by other CCGs during the evaluation period revealed sim-
ilar results to those observed when comparing the pathway
and standard care used by GPs within C&I (see Table 3 and sup-
plementary information).
Referrals made from Camden and Islington before and after
introduction of the NAFLD pathway
Due to the increased awareness of NAFLD in 2014–16 com-
pared to 2012–13, rates of referral to secondary care were anal-
ysed proportionate to the number of contemporaneously coded
019 vol. 71 j 371–378
NAFLD cases, rather than comparing the absolute numbers of
cases referred and detected per year.
In the year prior to pathway introduction, 79/83 (95.2%)
referrals made to secondary care were deemed unnecessary.
The impact of using age-adjusted FIB-4 thresholds
Subsequent to the design and implementation of the NAFLD
pathway the inﬂuence of age on FIB-4 was investigated, leading
to a recommendation to adjust the threshold of FIB-4 score in
people aged over 65.18 While adopting this higher threshold
would have reduced the number of unnecessary referrals to sec-
ondary care by 29 from 122 to 93, (23% reduction), this would
result in the loss of 12 cases with advanced ﬁbrosis of which
4 had cirrhosis (Table 2).
<1.30
1,022
FIB-4
1,452 patients
1.30-3.25
387
>3.25
43
ELF<9.5155
>9.5
232
HIGH risk of
≥F3 fibrosis
LOW risk of
≥F3 fibrosis
Low risk ≥F3 :
1,177 (81.1%)
Primary care management
High risk ≥F3 :
275 (18.9%)
Recommend referral
Fig. 2. Primary care risk stratification using the Camden and Islington
NAFLD pathway 2014–2016. ELF, enhanced liver ﬁbrosis; FIB-4, Fibrosis-4;
NAFLD, non-alcoholic fatty liver disease. (This ﬁgure appears in colour on
the web.)
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OF HEPATOLOGYFollowing introduction of the NAFLD pathway over a period of
2 years, the number of unnecessary referrals fell to 107/152
(70.4%) representing an 88% reduction when the pathway was
followed (OR 0.12; 95% CI 0.042–0.349; p <0.0001) (Tables 2,3).
The improvement in selection of cases of advanced ﬁbrosis led
to an increase in the number of cases of cirrhosis detected from
3/83 (3.6%) to 22/152 (14.5%), a 74% improvement
(OR 0.259; 95% CI 0.075–0.892; p = 0.0323) representing 8 addi-
tional cases of cirrhosis per year.
There were no statistically signiﬁcant differences in the out-
comes for patients managed using standard care before or after
introduction of the pathway suggesting that there was no
20Hawthorne or bystander effect from diffusion of the beneﬁts
of the pathway to patients managed using standard care.
NAFLD pathway
Excluded from
analysis
*
High risk ≥F3:
275
Specialist referral
N = 152
Specialist assessment
≤F2 fibrosis
107 (70.4%)
≥F3 fibrosis
45 (29.6%)
Fig. 3. Liver specialists’ evaluation of referrals to secondary care of NAFLD ca
NAFLD, non-alcoholic fatty liver disease. (This ﬁgure appears in colour on the w
Journal of Hepatology 2Modelling of the impact of other ELF thresholds
The effect of using the ELF threshold proposed by NICE (10.51)19
and the manufacturers of ELF (9.8)21 rather than the threshold
selected by the NAFLD pathway working group was investigated
in the referral population (Table 4). Employing a threshold of 9.8
would have avoided 11 (7.2%) unnecessary referrals but with a
concomitant loss of 3 (6.7%) cases of advanced ﬁbrosis. Use of an
ELF threshold of 10.51 would reduce the number of inappropri-
ate referrals by 34 (22%), at a cost of missing 10 cases of
advanced ﬁbrosis (22%) comprising 7 cases of F3 ﬁbrosis and 3
cases of cirrhosis.
Discussion
In this study, we report the results of a prospective, pragmatic,
real world pathway to triage patients with NAFLD in primary
care using non-invasive ﬁbrosis tests based on their risk of
advanced ﬁbrosis. This represents the largest reported primary
care cohort of patients with NAFLD to date. The NAFLD pathway
reduced the proportion of unnecessary referrals of NAFLD cases
while at the same time improving the detection of advanced
ﬁbrosis and cirrhosis. When the NAFLD pathway was followed,
it resulted in a reduction in unnecessary referrals by 81%, a
5-fold increase in the referral of cases of advanced ﬁbrosis and
cirrhosis and a 3-fold improvement in the detection of cases
of cirrhosis.Prior to introduction of the pathway, the vast majority of
referrals made to secondary care hepatologists could have been
Standard care
C&I standard care
other CCG’s
≤F2 fibrosis
434 (92.3%)
≥F3 fibrosis
36 (7.7%)
Specialist referral
N = 470
Specialist assessment
ses in the evaluation period 2014–2016. CCG, clinical commissioning group;
eb.)
019 vol. 71 j 371–378 375
The NAFLD pathway working group elected to use blood
Following introduction of the pathway, only 19% of cases of
NAFLD diagnosed in primary care were deemed suitable for
A
C
care care CCGs
329 293 470 622 93
2
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Research Article Genetic and Metabolic Diseasesmanaged in primary care. We believe that this pattern of refer-
ral is common for NAFLD. Reducing inappropriate referrals rep-
resents an opportunity to reduce unnecessary investigations,
inconvenience and even harm for patients, pressure on sec-
ondary care services and costs for the healthcare system. The
NAFLD pathway processed 1,452 patients in 2 years demon-
strating the ability to function at scale and manage the rising
prevalence of NAFLD.
Compared to other studies in the general population, this is
the ﬁrst that speciﬁcally focused on patients with established
NAFLD and also provided a comprehensive algorithm for refer-
ral to secondary care. Other studies in primary cared screened
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Fig. 4. Evaluation of patients referred to secondary care from Camden and
Islington 2014–2016. NAFLD, non-alcoholic fatty liver disease.
Table 2. Clinical estimates of liver fibrosis for patients diagnosed with N
pathway.
2012–2013
C&I Other
CCGs
All
CCGs
C&I
pathway
C&I standard
care
All
n = 83 109 192 152 177
<F3 79 100 179 107 163
<F3% 95.2 91.7 93.2 70.4 92.1
F3&F4 4 9 13 45 14
F3&F4% 4.8 8.3 6.8 29.6 7.9
F4 3 4 7 22 10
F4% 3.6 3.7 3.6 14.5 5.6
C&I, Camden and Islington; CCG, clinical commissioning group; FIB-4, Fibrosis-4 sco
Table 3. Impact of implementation of the Camden and Islington NAFLD pa
Intervention Comparator Referrals avoided
Proportion (%) 95% CI p value
C&I pathway C&I before 88 75–96 0.0001
C&I pathway C&I standard care 80 61–89 <0.0001
C&I pathway Other CCGs 81 66–89 <0.0001
All of C&I Other CCGs 77 35–92 0.006
C&I, Camden and Islington; CCG, clinical commissioning group; NAFLD, non-alcoholi
groups compared to the listed ‘‘Comparator” groups.376 Journal of Hepatology 2patients with risk factors for NAFLD or alcohol-related liver dis-
ease or general population cohorts based on speciﬁc age cut-
offs.22 Moreover, most such studies have failed to report on
the outcome of positive screening results, i.e. on the proportion
of patients who truly had advanced ﬁbrosis or cirrhosis.
Table 4. Impact of using different ELFTM thresholds for patient
stratification.
ELF ≥9.8 ELF ≥10.51
Relative to ELF ≥9.5 n % n %
Referrals avoided 11 7.2 34 22.4
Missed cases of F3/F4 ﬁbrosis 3 6.7 10 22.2
Missed cases of cirrhosis 0 3 13.6
ELF, enhanced liver ﬁbrosis.tests to stratify liver ﬁbrosis severity rather than transient elas-
tography that has been used in other successful pathways.23
Blood tests have the advantages that they are easily incorpo-
rated into routine investigations in primary care, require no spe-
cialist equipment, training or operation and have a lower
diagnostic failure rate compared to elastography-based meth-
ods including FibroScan, which has failure rates of between 5–
15%, especially in NAFLD.24 Application of the ﬁrst stage ‘‘sim-
ple” and inexpensive test, FIB-4, allowed us to prevent referral
of 70.3% of cases of NAFLD detected in primary care who did
not have evidence of advanced ﬁbrosis. However, use of FIB-4
alone only permitted the selection of just 3.0% of cases for refer-
ral to secondary care with high probability of cirrhosis. Addition
of the ‘‘direct biomarker” ELF test was only required in 26.7% of
cases in the pathway, but the additional use of ELF avoided
inappropriate referral for 40.1% of those with indeterminate
FIB-4 results. It is therefore important to underline that over
two-thirds of patients with NAFLD can be reassured with the
use of readily available inexpensive tests.FLD before and after introduction of the Camden and Islington NAFLD
2014–2016 Age adjusted FIB–4
&I Other CCGstandard All standard All C&I path FIB-4 >2.070 271 434 541 60
.1 92.5 92.3 87 64.5
59 22 36 81 33
.9 7.5 7.7 13 35.5
32 15 25 47 18
.7 5.1 5.3 7.5 19.4
; NAFLD, non-alcoholic fatty liver disease.way.
Advanced fibrosis/cirrhosis detection Cirrhosis detection
OR 95% CI p value OR 95% CI p value
8.30 2.87–24.05 0.0001 4.51 1.31–15.56 0.017
4.90 2.56–9.36 <0.0001 2.83 1.29–6.18 0.0092
5.18 2.97–9.04 <0.0001 3.14 1.57–6.24 0.0011
4.32 1.52–12.25 0.006 2.87 0.86–9.62 0.0871
atty liver disease; OR, odds ratio. Odds Ratios were calculated for the ‘‘Intervention”019 vol. 71 j 371–378
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OF HEPATOLOGYreferral to secondary care. Although not appropriate to compare
this proportion with referral practice prior to the pathway intro-
duction, it is noteworthy that using the same criteria, 93% of
patients referred to secondary care prior to the pathway intro-
duction were judged to have been unnecessary.
The beneﬁcial effects of the pathway were restricted to cases
that followed the pathway. During the evaluation period,
despite evidence of improved awareness of NAFLD, suggested
by increased coding of NAFLD, there was no evidence of
improvement in case detection or any reduction in unnecessary
referrals when standard care was followed rather than the path-
way. This demonstrates the value of use of the pathway but also
shows that there was no diffusion of the pathway beneﬁts to
patients managed with standard care or any signiﬁcant change
in ‘‘standard” practice due to emerging awareness of NAFLD
during the evaluation period.Only 48% of referrals from C&I were made using the NAFLD
pathway. Despite this, introduction of the pathway produced
signiﬁcant improvements in referral practice even when refer-
rals made using standard care were included in the analysis.
This demonstrates the success of the service improvement
delivered in the context of routine clinical care despite moder-
ate adoption and suggests that the results are generalizable.
More widespread use of the NAFLD pathway could result in
even greater improvements in efﬁciency and the detection of
cases of advanced ﬁbrosis. This might be achieved with more
extensive efforts to disseminate the pathway and insistence that
the pathway should be adopted for all NAFLD referrals.
Use of an age-adjusted FIB-4 threshold or of a higher ELF
threshold according to the manufacturer’s or the NICE recom-
mendations would have improved the positive predictive value
of the NAFLD pathway for detection of advanced ﬁbrosis at the
expense of an increased number of false negative cases. We
believe that the use of such thresholds is not justiﬁed in this
context as the reduction in referral numbers carries signiﬁcant
risks of missing cases that would beneﬁt from specialist care
and would be difﬁcult to implement in primary care. Individual
healthcare commissioners may decide to prioritize the detec-
tion of advanced ﬁbrosis and long-term cost effectiveness over
shorter term cost savings associated with avoiding referral of
patients with lesser degrees of ﬁbrosis.
Prior to introduction of the NAFLD pathway, funders
expressed concern that the pathway might lead to a marked
increase in referrals to secondary care leading to greater costs.
Despite an increase in the diagnosis of NAFLD between 2012–
2016 denoted by the increase in the coding of patients for
NAFLD, use of the pathway resulted in a 3% reduction in the pro-
portion of NAFLD cases that were referred to secondary care per
year whether or not the pathway was followed, with only a
modest increase in the total number of patients referred.
The strengths of this study include the prospective collection
of real-world data, the size of the cohort, which is the largest
primary UK cohort with regards to NAFLD, and the engagement
of appropriate stakeholders in the pathway design.
The limitations mostly stem from the nature of the imple-
mentation design, which was designed to evaluate a health ser-
vice innovation. It was not possible to conduct a randomized
controlled trial because of the commitment to adopt the path-
way once it was discussed with GPs and public health clinicians
who formed the opinion that there was sufﬁcient evidence to
implement the pathway without a trial. This view was subse-
quently endorsed by NICE in the NAFLD Guidance24.
Journal of Hepatology 2The NAFLD pathway evaluation lacked a hard outcome mea-
sure of liver ﬁbrosis and rather used the composite clinical
judgement of an expert clinician blinded to the pathway use.
The secondary care evaluation of the included patients thus
reﬂects real-world practice, with an inevitable degree of selec-
tion bias in the patients undergoing liver biopsy.
Similarly, the lack of formal evaluation of the prevalence of
ﬁbrosis amongst patients allocated to remain in primary care
prevented assessment of the ‘‘false negative” rate for the path-
way allocation. However longer term follow-up for clinical out-
comes and more detailed health economic analyses will reveal
the clinical impact of stratiﬁcation and the true cost effective-
ness of the pathway. Patient and service provider acceptance
is being gathered and will be reported in due course.
Conclusions
The C&I NAFLD pathway improved the selection of patients with
advanced ﬁbrosis and cirrhosis for referral to secondary care,
reducing unnecessary referrals. This in turn delivers improve-
ments in the detection of serious liver damage, better use of
healthcare resources and immediate cost savings. The reduction
in referrals to secondary care reduces strain on services that are
confronting a rising prevalence of obesity and NAFLD as well as
improving patient experiences by avoiding unnecessary clinic
appointments and investigations. This is the ﬁrst study to incor-
porate the British Society for Gastroenterology guidance on the
management of NAFLD and validates the recommendation to
use FIB-4 and ELF for 2-stage stratiﬁcation. The NAFLD pathway
is highly generalizable, as GPs will have access to both FIB-4 and
ELF tests through most biochemistry laboratories.
It remains to be seen if the use of the NAFLD pathway deliv-
ers beneﬁts in terms of a reduction in the incidence and compli-
cations of NAFLD cirrhosis.
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